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Available online 27 November 2018Background: Nanomedicine offers an excellent opportunity to tackle treatment-refractory malignancies by en-
hancing the delivery of therapeutics to the tumor site. High endothelial venules (HEVs) are found primarily in
lymph nodes or formed de novo in peripheral tissues during inﬂammatory responses. They express peripheral
node addressin (PNAd), which is recognized by the monoclonal antibody MECA79.
Methods: Here, we demonstrated that HEVs form de novo in human pancreatic ductal adenocarcinoma (PDAC).
We engineered MECA79 coated nanoparticles (MECA79-NPs) that recognize these ectopic HEVs in PDAC.
Findings: The trafﬁcking of MECA79-NPs following intravenous delivery to human PDAC implanted in a human-
ized mouse model was more robust than non-conjugated NPs. Treatment with MECA79-Taxol-NPs augmented
the delivery of Paclitaxel (Taxol) to the tumor site and signiﬁcantly reduced the tumor size. This effect was asso-
ciated with a higher apoptosis rate of PDAC cells and reduced vascularization within the tumor.
Interpretation: Targeting the HEVs of PDAC usingMECA79-NPs could lay the ground for the localized delivery of a
wide variety of drugs including chemotherapeutic agents.
Fund:National Institutes of Health (NIH) grants: T32-EB016652 (B·B.), NIH Cancer Core Grant CA034196 (L.D.S.),
National Institute of Allergy and Infectious Diseases grants R01-AI126596 and R01-HL141815 (R.A.).nter, Br
.
. This is©2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Taxol1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) belongs to a lethal family
of cancers [1,2], and it is estimated to become the secondmost common
cause of cancer deaths by 2030 [3]. Although advanced surgical tech-
niques, combinational chemotherapeutic agents, and adjuvant thera-
pies have been employed to tackle this deadly disease, the overall
prognosis of PDAC has remained unsatisfactory [4]. Nearly 80% of
PDAC patients have an unresectable tumor at the time of diagnosis [2],
and these patients experience a ﬁve-year survival of about 8% for all
stages combined [5]. Among several obstacles that have plagued prog-
ress toward an effective therapy, an important factor hindering theigham and Women's
an open access article underpenetration of chemotherapy drugs has been poor vascularization asso-
ciated with the dense tumor tissuemicroenvironment [6–8]. One of the
key features of PDAC is over-production of extracellularmatrix ﬁbers by
pancreatic stellate cells, referred to as a desmoplastic reaction, which
can result in a ﬁbrotic and hypo-vascular environment that contributes
to low drug penetration and delivery [9,10].
Nanotechnology provides opportunities to tackle treatment-
refractory conditions, such as cancer, through smart systems of delivery
for relevant drugs to the tumor sites. The majority of the earliest anti-
cancer nanocarriers were designed on the basis of the enhanced perme-
ability and retention (EPR) effect [11,12]. EPR delivery systems rely on
the long-standing observation that tumor vasculature is leaky and
thereby allows for high penetration of drugs within the tumor environ-
ment [13]. However, recent studies have questioned the role of EPR as a
dominantmechanism that governs the trafﬁcking of drugs to the site of
the tumor [14]. For instance, the porosity of tumor vasculature has been
found to be dependent on the individual tumor model. In addition, thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Thehigh endothelial venule (HEV) is a highly specialized blood ves-
sel found only in the lymph nodes (LN) and tonsils of healthy indi-
viduals. Assessment of the presence of HEVs in cancer tissues
including PDAC has gained considerable interest recently. We
have shown previously that MECA79 monoclonal antibody
(mAb)-coated particles localize to the LN, where MECA79 mAb
recognizes PNAd molecules expressed on the surface of the
HEVs.
Added value of this study
Our data support the notion that the desmoplastic region of PDAC
contains HEVs. Here, for the first time, we demonstrate that
MECA79 mAb-coated particles home to implanted human PDAC
in humanizedmice. TreatmentwithMECA79-Taxol-NPs improved
the efficacy of Paclitaxel significantly in suppressing the growth of
PDAC.
Implications of all the available evidence
Our HEV-targeted platform of therapeutic delivery carries signifi-
cant transformative potential in improving the treatment of
PDAC, one of the most refractory human cancers.
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potentially the delivery of the drug to the tumor to aminiscule percent-
age (b1%) of the administered amount [15].
Active, targeted delivery often relies on surface modiﬁcation of the
NPs with an antibody or peptide to interact with a ligand or receptor
of interest [16]. The interaction of NPs with an endothelial cell repre-
sents an early locus that can control the trafﬁcking of circulating NPs
to the targeted tissue. A limitation with this method of delivery is the
ubiquitous expression of common molecules by endothelial cells,
which may increase the rate of off-target effects [8].
The high endothelial venule (HEV) is a highly specialized blood ves-
sel that is found only in the lymph nodes (LN) and tonsils in the usual
healthy state [17]. In contrast to normal venules that contain ﬂat endo-
thelial cells, HEVs contain cuboid endothelial cells of greater height that
express a series of sialyl-LewisX-coated proteins, referred to as periph-
eral node addressin (PNAd) molecules [17]. MECA79 is a monoclonal
antibody (mAb) that recognizes all of the PNAdmolecules [18]. Interest-
ingly, HEVs are also formed ectopically in chronically inﬂamed tissues as
well as in a wide variety of cancers including PDAC [19–22]. We have
previously shown that microparticles coated with MECA79 localize to
lymph nodes through their interaction with HEVs [23]. Given that
MECA79 mAb also recognizes the ectopic HEVs in the tumors, we hy-
pothesized that MECA79-coated NPs can home to PDAC by binding to
the HEV structures in these tumors. Thus, MECA79-coated NPs afford
opportunities to deliver chemotherapeutics to PDAC.2. Materials and methods
2.1. Cell line, mice and human PDAC tissue
Human pancreatic adenocarcinoma cell line BxPC-3 (CRL-1687)was
purchased from American Type Culture Collection (ATCC). NOD.Cg-
PrkdcscidIL2rgtm1Wjl/SzJ (NSG) (JAX#005557) mice were obtained from
The Jackson Laboratories. Male or female mice were used at
6–10weeks of age and housed in sterilized, ventilated cages in a speciﬁcpathogen-free animal facility under a standard 12 h light/12 h dark
cycle. Micewere fed irradiated food andwater ad libitum. All animal ex-
periments and methods were performed in accordance with the rele-
vant guidelines and regulations approved by the Institutional Animal
Care and Use Committee of Brigham and Women's Hospital, Harvard
Medical School, Boston, MA. Human pancreatic ductal adenocarcinoma
tumors for research purposes were collected at the University of Massa-
chusetts Medical School under informed consent IRB ID: H00004721.
The specimens were completely anonymous and had no direct identi-
ﬁers and no codes or indirect identiﬁers that link back to subjects.
2.2. Synthesis of MECA79 conjugated NP
The poly(D,L-lactic-co-glycolic) acid (PLGA)-based copolymers were
purchased from PolySciTech®, Akina Inc. Methoxy Poly (ethylene gly-
col)-b-PLGA copolymer (mPEG-PLGA, MW 5,000:30,000 Da, 50:50 LA:
GA (w:w)) and PLGA-b-poly(ethylene glycol)-maleimide (PLGA-PEG-
MAL, Mw ~30,000–5,000 Da, 50:50 LA:GA (w:w)) were used as the
core polymers. The NPs were engineered using self-assembly single
step nanoprecipitation. PEG-PLGA and maleimide-PEG-PLGA were dis-
solved in acetone. Paclitaxel (Taxol) (LC Laboratories, USA), Oregon
Green™ 488 Conjugate (Oregon Green™ 488 labeled Taxol, Flutax-2,
ThermoFisher Scientiﬁc, US, referred to as *Taxol), or IRDye 800CWCar-
boxylate (LI-COR, USA) was added to the polymer mixture, vortexed
and then added dropwise to a 0.015% aqueous solution of polyvinyl al-
cohol under vigorous stirring to formulate Taxol-NPs, *Taxol-NPs, or
IR800-NPs. Then, the NP suspension was stirred for 2 h, and the NPs
were concentrated by centrifugation using Amicon Ultra-15 centrifugal
ﬁlter units (MWCO100 kDa; Sigma-Aldrich) at 3,750 × rpm in intervals
of 5 min. The resulting NPs were washed with Dulbecco's phosphate-
buffered saline (DPBS) (Mediatech, Inc., Manassas, VA) and resus-
pended in 1 mL of DPBS.
The anti-mouse/human PNAd antibody (MECA79, NOVUS Biologi-
cals) was conjugated to the functional group of NPs using thiol-
maleimide chemistry. Tris(2-carboxyethyl)phosphine hydrochloride
(TCEP, 0.5 M, Sigma-Aldrich) was used to cleave thiol groups of
MECA79 mAb. 30 μg of MECA 79 mAb was mixed with 30 μl of TCEP
and incubated for 15 min at room temperature, then it was mixed
with the NP suspension. The MECA79-NPs were stored at 4 °C prior to
use.
2.3. Characterization of NPs
The size distribution of NPs was determined using Dynamic Light
Scattering (DLS) as previously described [24]. The morphology of NPs
was observed by transmission electron microscopy (TEM). Freshly pre-
paredNPswere deposited on 200-mesh Formvar/carbon-coated copper
grids and negatively stainedwith 0.75% uranyl formate stain, before im-
aging with a Tecnai G2 Spirit BioTWIN electron microscope equipped
with an AMT 2 k CCD camera and low-dose software. The loading of
Taxol was determined using ultraviolet-visible (UV-VIS) spectropho-
tometer as previously described [24]. A calibration curve of the absor-
bance at 230 nm for various concentrations of Taxol was prepared.
The absorbance of the supernatants and samples were compared with
this calibration curve to determine the loading efﬁciency of Taxol.
2.4. Release kinetics of Taxol
To quantify the release proﬁle of Taxol from the NPs, *Taxol-NPs or
MECA79-*Taxol-NP were incubated at 37 °C in triplicate. At
predetermined time intervals, the NPs were removed, transferred to
Amicon Ultra-15 centrifugal ﬁlter units (MWCO 10 kDa; Sigma-
Aldrich), and centrifuged at 3,750 × rpm for 5 min. The ﬁltrate was an-
alyzed with a UV-VIS spectrophotometer, and absorbance was mea-
sured at 488 nm to determine the amount of released Taxol at each
time point.
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The standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide (MTT) protocol was utilized to assay the cell viability.
Brieﬂy, the BxPC-3 cell line was cultured in a 96-well plate (2 × 105
cells/well) and incubated at 37 °C in 5% CO2 overnight. Next, empty
NPs, Taxol-NPs and free Taxol were added to the cells and incubated
at 37 °C in 5% CO2 for 24 h. Then, the MTT solution (5 mg/ml) was
added to each well, and the cells were incubated for another 4 h.
Upon removal of the MTT solution, the formed formazan crystals were
solubilizedwith isopropanol for 15min, and the proportion of formazan
to the number of viable cells was determined by an absorbance micro-
plate reader (Versa MAX, Molecular Devices).2.6. Pancreatic tumor implantation
The human PDAC tumor was cut into 3–5 mm3 pieces with a razor
blade on a sterilized petri dish. A small incision was made in the skin
on the lower back of NSGmice, and the PDAC tumorwas implanted sub-
cutaneously. The tumor growthwasmonitored three times perweek by
digital caliper (Fisherbrand™Traceable™Digital Calipers).2.7. In vivo targeting of human PDAC by NPs
To study the trafﬁcking of NPs, the tumor-bearing mice were
anesthetized via inhalation of isoﬂurane/oxygen, and IR800-NPs or
MECA79-IR800-NPs were administered intravenously. The trafﬁcking
of the ﬂuorescently labeled NPs was studied using a UVP iBox®
Explorer2™ Imaging Microscope equipped with a 750–780 nm excita-
tion ﬁlter and an 800 nm long-pass emission ﬁlter. For live imaging,
mice were anesthetized and placed inside the dark box in prone
position. For ex vivo imaging, the mice were sacriﬁced via carbon diox-
ide inhalation and cervical dislocation. Then, the pancreatic tumors
were harvested for imaging.2.8. Immunoﬂuorescence and Immunohistochemistry staining of tumor
Frozen OCT blocks of tumors were cut using a cryostat into 8-μm
thick sections and were stained using anti-PNAd (MECA79), anti-
human CD31 (WM59, BioLegend), anti-Caspase-3 (4-1-18, BioLegend),
anti-Collagen I (abcam), anti-Collagen IV (abcam), anti-Fibronectin
(abcam), anti-alpha smooth muscle Actin (α-SMA, abcam), HECA 452
(HECA-452, BioLegend), anti-human HLA-A,B,C antibody (W6/32,
BioLegend) and anti-mouse/humanKi-67 (11F6, BioLegend) antibodies.
DAPI (VECTASHIELD, Vector Laboratories Burlingame, CA) was used to
stain the cell nuclei. The stained tissue sections were imaged using a
ﬂuorescent confocal microscope and an EVOS FL2 auto microscope.
For immunohistochemistry (IHC) staining, the human post-mortem
PDAC samples were stained with anti-mouse/human PNAd (MECA79).2.9. PDAC treatment
When the size of the implanted tumor reached 8 mm in diameter,
the mice were randomized into different groups and given speciﬁed
treatments: Group #1 was the control and received no treatment;
Group #2 received free Taxol; Group #3 received Taxol-NPs; and
Group #4 received MECA79-Taxol-NPs. All mice received intravenous
injections three times a week for two weeks, followed by twice a
week for one week. The Taxol dose was ﬁxed at 0.5 mg/kg among
Groups #2–4. The body weight and tumor size of the animals were
monitored throughout the treatment course.
Antitumor activity was evaluated in terms of tumor volume (V), in
which l, w, and h are the length, width, and height of the tumor asmeasured by a digital caliper, deﬁned as
V ¼ lw h
The tumor growth inhibition (TGI), in which Vc and Vt are the vol-
ume of the control tumor and tumor in treated groups at the end of
the study, respectively, and Vo is the average starting volume, was
thus estimated as follows
TGI %ð Þ ¼ Vc−Vtð Þ
Vc−Voð Þ  100
2.10. RT-PCR assay
RNA was isolated with TRIZOL (Invitrogen), and the ﬁrst strand of
cDNA was synthesized using 1 μg of RNA and High-Capacity Reverse
Transcriptase (Invitrogen). RT-PCR was performed with SYBR Green
PCR reagents. RNA levels were normalized to the level of GAPDH and
calculated as delta-delta threshold cycle (ΔΔCT). Primers used for RT-
PCR are listed as follows: GAPDH-For: AGCCACATCGCTCAGACAC,
GAPDH-Rev: GCCCAATACGACCAAATCC; VEGF-For: CTACCTCCACCATG
CCAAGT, VEGF-Rev: GCAGTAGCTGCGCTGATAGA; All RT-PCR reactions
were performed in triplicate.
2.11. Statistics
Two-way ANOVA or one-way ANOVA analysis were used for
comparison of experimental groups. Student's t-test was used for com-
parison of two groups. Differences were considered to be signiﬁcant for
*p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. Prism software was used for data
analysis and to prepare graphs (GraphPad). Data represent mean ±
SEM.
3. Results
3.1. Presence of ectopic HEVs in PDAC
As outlined above, HEVs are formed newly in some malignancies,
including PDAC [25]. This characteristic provides an unprecedented op-
portunity to test the efﬁcacy of HEV-targeted delivery for the treatment
of PDAC. We screened six post-mortem PDAC samples. All of these tis-
sues contained de novoHEVs,when analyzed by immunohistochemistry
staining of PNAd (marked with asterisks in Fig. 1a, 1–6). The cuboid en-
dothelial cells of the HEV can be observed in a high-magniﬁcation IHC
image of a PNAd+ vessel in the PDAC tumor (Fig. 1b).
We propagated PDAC tumor samples (using NSG mice) from a
tumor that was resected from a patient with advanced PDAC. Implants
were placed in NSG mice, and the tumor was removed to assess the
presence of HEV post-implantation. Immunohistochemistry showed
the presence of de novo HEVs (ectopic HEVs) in this PDAC sample
(Fig. 1c). Further localization of the PDAC via immunoﬂuorescence
staining showed the presence of HEVs within the dense desmoplastic
regions of the tumor (Fig. 1d). The HEV structures were detectedwithin
the dense extracellular matrix (ECM) of the PDAC, as evidenced by
staining the ECM components with ﬁbronectin and α-smooth muscle
actin (α-SMA), as shown in Fig. 1d [26]. To prove further that these
vascular structures were HEVs, we also used HECA452 antibody (recog-
nizes sialyl Lewisx), which stained the structures that were identiﬁed as
HEVs (Supplementary Fig. 1a). The use of human Class I HLA antibody
revealed that the HEVs co-stained with anti PNAD antibody, suggesting
that at least a portion of these HEVs remain of human origin (Supple-
mentary Fig. 1b).
Fig. 1. Immunohistochemistry and immunoﬂuorescence analysis of human PDAC. (a) Representative images from immunohistochemistry analysis of human PDAC samples from post-
mortem showing ectopic PNAd+ venules (marked by * in the images, n = 6, scale bar = 100 μm). (b) A representative high-magniﬁcation IHC image of a PNAD+ vessel in the PDAC
(Scale bar = 75 μm). (c) Immunohistochemistry staining of the human PDAC prior to implantation into the NSG mice conﬁrming PNAd expression in the tissue. (d) Representative
images of PNAD+ vessels (green) surrounded by Fibronectin (red) and αSMA (red) (Scale bar = 100 μm).
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Next, we tested the capacity of MECA79-NPs to localize to human
PDAC following implantation into NSG mice. The PDAC-bearing NSG
mice were injected with MECA79-IR800-NPs or non-conjugated
IR800-NPs intravenously and imaged after 24 h. MECA79-IR800-NPs
trafﬁcked to the PDAC at a greater rate than that of the untreated controland non-conjugated IR800-NPs (n=4mice/group) (Fig. 2a). Themean
ﬂuorescence intensity (MFI) of the PDAC in the MECA79-NP-injected
mice was signiﬁcantly higher than the mice injected with
non-conjugated IR800-NPs (4.5 ± 0.5 × 104 vs.1.1 ± 0.2 × 104,
***p b 0.001, student's t-test, n = 4 mice/group) (Fig. 2b). We
also examined PDAC tissue to assess the pattern of trafﬁcking of
MECA79-IR800-NPs. The MECA79-IR800-NPs (in red) were localized
Fig. 2. Targeted delivery of NP to the PNAd-expressing HEV in PDAC. (a)Whole-body NIR ﬂuorescent imaging showing higher trafﬁcking of MECA79-IR800-NPs to PDAC, as compared to
non-conjugated IR800-NPs. The dashed area in each image represents the PDAC tumor in vivo and ex vivo post-harvest, respectively. (b) Corresponding MFI of the tumor showing a
signiﬁcant increase in trafﬁcking of MECA79-IR800-NPs, as compared to the non-conjugated IR800-NPs. The data are presented as the mean and SEM (n = 3). (***p b 0.001, student's
t-test). (c) Representative immunoﬂuorescence micrograph of the tumor 24 h post-injection of MECA79-IR800-NPs (red) demonstrates their presence around HEV (green). The red ar-
rows point to the areas of MECA79-IR800-NP accumulation in the tumor (Scale bar = 100 μm).
83B. Bahmani et al. / EBioMedicine 38 (2018) 79–88to the vicinity of HEVs (in green) in the tumor (Fig. 2c). The arrows
point to the areas of accumulation of MECA79-IR800-NPs in the
tumor section.
3.3. Synthesis and characterization of MECA79-Taxol-NPs
We evaluated whether our model of targeted trafﬁcking of NPs re-
sults in increased delivery and improved efﬁcacy of a chemotherapeutic
drug. We synthesized PLGA-based NPs encapsulating paclitaxel (Taxol-
NPs). Fig. 3a shows the electron microscopy imaging of Taxol-NPs with
spherical shape. The surface of theNPswas thenmodiﬁedwithMECA79
mAb to form a delivery platform to target HEVs within PDAC. The
average size of MECA79-Taxol-NPs was signiﬁcantly higher than the
Taxol-NPs (123.7 ± 8.2 nm vs. 80.9 ± 2.8, **p b 0.01, student's t-test,
n = 5/group) (Fig. 3b). The Taxol was released from the NPs in a
sustained manner during a one-week time period (Fig. 3c). The loading
efﬁcacy of Taxol in the NPs varied between 15%–30%.
Next, we tested the efﬁcacy of Taxol-NPs in killing pancreatic adeno-
carcinoma cells in vitro using the MTT assay. The Taxol-NPs were as ef-
fective as free Taxol and resulted in signiﬁcant tumor cell death
(Fig. 3d).Oregon Green™ 488 Taxol (*Taxol) was used to conﬁrm the
targeted delivery of Taxol to tumor. Either *Taxol or MECA79-*Taxol-
NP was injected intravenously into PDAC-bearing NSG mice, and tu-
mors were harvested 24 h post-injection for ex vivo imaging. The
MFI of tumors was signiﬁcantly higher in the MECA79-*Taxol-NP
group, as compared to the *Taxol group (Fig. 3e). Immunoﬂuorescence
imaging of the PDAC tissue showed that more MECA79-*Taxol-NPs
were present within the ECM of the tumor, as compared to the control
group (Fig. 3f).
3.4. Therapeutic efﬁcacy of MECA79-Taxol-NPs
We investigated the efﬁcacy of MECA79-Taxol-NPs in the treatment
of PDAC in NSG mice. Tumors were implanted into NSG mice, and the
mice were randomized on the basis of tumor size and assigned to four
different groups: control (no treatment), free Taxol, Taxol-NPs, and
MECA79-Taxol-NPs.
The results demonstrated amarked reduction in the size of the PDAC
during the course of treatment. The size of the tumor at the end of
the study was signiﬁcantly lower in mice treated with MECA79-Taxol-
NPs (1.4 ± 0.4 × 103 mm3), as compared to the no treatment group (6
Fig. 3. Formulation and characterization of MECA79-Taxol-NPs. (a) Representative TEM images of Taxol-NP (Scale bar = 100 nm) (b) Hydrodynamic diameter of non-conjugated and
MECA79-conjugated Taxol-NPs. The data are presented as the mean and SEM (n = 6). (c) Release kinetics of Taxol from NPs over one-week. The data are presented as the mean and
SEM (n = 3). (d) Taxol-NPs induced similar levels of apoptosis in pancreatic cancer cells in vitro in comparison to free Taxol. (e) The MFI of tumors showed signiﬁcantly higher
accumulation of *Taxol in MECA79-*Taxol-NP group, as compared to *Taxol group (*p b 0.05, student's t-test). The data are presented as the mean and SEM (n = 3). (f) Immunoﬂuores-
cence staining of PDAC tissue showed that MECA79-*Taxol-NPs (green) were present within the ECM (Collagen IV, in red) of tumor at a higher number, as compared to the control group
(Scale bar = 100 μm).
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× 103 mm3), or the Taxol-NP treatment group (4.2 ± 1.3 × 103 mm3,
***p b 0.001, ANOVA, n = 5 mice/group) (Fig. 4a). Non-conjugated
Taxol-NP treatment, which relies solely on the EPR effect, was not effec-
tive, and the average size of the tumor in this group was similar to no
treatment and free Taxol treatment groups. Furthermore, the ﬁnal
weight of the tumors in the mice treated with MECA79-Taxol-NPs was
signiﬁcantly smaller in comparison to the no treatment, free Taxol,
and Taxol-NP treatment groups (Taxol dose = 0.5 mg/kg, *p b 0.05,
**p b 0.01, ANOVA, n = 5 mice/group) (Fig. 4b). Representative images
of tumors from each group at the end of the study are shown in Fig. 4b.
Finally, we calculated the tumor growth inhibition rate for each
treatment group. The tumor growth inhibition rate almost doubledwhen mice were treated with MECA79-Taxol-NPs, as compared to the
mice treated with a similar dose of free Taxol (68.02 ± 1.8 vs.36.91 ±
0.5, ***p b 0.001, student's t-test, n = 5 mice/group).
3.5. Immunoﬂuorescence characterization of the PDAC
Assessment of the tumor tissue by immunoﬂuorescence staining
post-treatment revealed the presence of more apoptotic cells (cas-
pase-3+, Fig. 5a) in the targeted treatment group in comparison to
the other groups. Caspase-3 is one of the cysteine proteases associated
with Taxol-induced programmed cell death [27]. The percentage of
caspase-3+ cells doubled when the mice were treated with
MECA79-Taxol-NPs (66.42 ± 2.84%), as compared to Taxol-NPs
Fig. 4. Therapeutic efﬁcacy of MECA79-Taxol-NPs. (a) Improved efﬁcacy in delivering
Taxol to PDAC was observed in mice treated with MECA79-Taxol-NPs, as compared to
no treatment, free Taxol, and Taxol-NPs (Taxol dose =0.5 mg/kg, ***p b 0.001, ANOVA,
n = 5 mice/group). Arrows indicate the days of treatment. The data are presented as
the mean and SEM. (b) The ﬁnal weight of the tumor in mice treated with
MECA79-Taxol-NPs was signiﬁcantly lower, as compared to the no treatment, free Taxol,
and Taxol-NP treatment groups. (*p b 0.05, **p b 0.01, ANOVA, n = 5 mice/group). The
data are presented as the mean and SEM.
85B. Bahmani et al. / EBioMedicine 38 (2018) 79–88(29.25 ± 2.17%) and free Taxol (36.58±2.74%) (Fig. 5b). Apoptotic cells
were located in close proximity to the vasculature (CD31+ and HEV,
Fig. 5c). In addition, immunoﬂuorescence staining of the PDAC using a
cellular marker of proliferation (Ki67) demonstrated a higher percent-
age of Ki67+ cells in the Taxol-NP group, as compared to the MECA79-
Taxol-NP group (47.7 ± 2.9% vs. 14.4 ± 1.8%, ***p b 0.0001, student's
t-test) (Fig. 5a and d). Proliferating cells were located around the
CD31+ vasculature, but we observed very few around the HEV (Fig. 5e).
The PDAC in mice treated with MECA79-Taxol-NPs also demon-
strated lower vascularization (CD31) as compared to the other groups
(Fig. 5a). To assess the activity of vascular cells, the expression levels
of VEGF genes were compared between the four groups. The expression
of VEGF downregulated signiﬁcantly in the tumor following treatment
with MECA79-Taxol-NPs, while the expression levels remained the
same in the no treatment, free Taxol, and Taxol-NP treatment groups
(Supplementary Fig. 2a). Diminished microvessel intensity and VEGF
expression levels have been reported previously as a result of Taxol
treatment [28]. Taken together, our ﬁndings that demonstrate higher
cellular apoptosis, along with lower cellular proliferation and vasculari-
zation, demonstrate efﬁcient delivery of Taxol to PDAC using our
targeted platform. To evaluate the changes in ECMdeposition, PDAC tu-
mors from the control and MECA79-Taxol-NP treatment groups were
stained for Collagen I. Interestingly, Collagen I deposition was de-
creased, and the matrix became thinner and disrupted in theMECA79-Taxol-NP treated mice as compared to the control group
(Fig. 5f).
4. Discussion
PDAC remains one of the most lethal malignancies [1,2]. Nearly 80%
of PDAC patients are not eligible for tumor resection at the time of
diagnosis, due to the presence of locally advanced disease or distantme-
tastases. The mainstay of treatment for patients with advanced PDAC is
palliative therapies, including chemotherapy and radiation [29].
Gemcitabine-based combination therapy has gathered momentum re-
cently, but the overall prognosis for PDAC remains dismal [30,31].
Therefore, the development of an innovative therapeutic strategy
aimed at improving the outcomes of PDAC patients constitutes a
major unmet need.
The use of NPs provides an opportunity to target various pathologi-
cal arms of PDAC. NPs can be modiﬁed for a number of variables to im-
prove their anti-tumor efﬁcacy, including charge, size, and shape
[32,33]. A few reports have described the use of NPs to counter resis-
tance toward gemcitabine. One method utilizes NPs to improve the
overall kinetics of gemcitabine (i.e., increasing its half-life) or to increase
the cellular uptake of gemcitabine by the tumor [34]. Others have for-
mulated polymeric NPs encapsulating curcumin, which increased its
systemic bioavailability and resulted in increased suppression of PDAC
in animals, as compared to free drugs [35]. The utility of NPs also centers
on their potential to target speciﬁc molecular targets of the cancer.
Epidermal growth factor receptor (EGFR) [36–39], Mucin 1 (MUC1)
[40], and Plectin-1 [41] are among the receptors on the surface of cancer
cells being used to target PDAC. These tumor cells are not in direct con-
tinuity with the blood.
The dense microenvironment of the PDAC is a key feature of PDAC
that contributes to its resistance to therapeutic agents [42]. The dense
stroma of PDAC (a result mainly of overproduction of ECM by stromal
cells) is largely hypovascular, which restrains the penetrance of thera-
peutics [43]. The dense microenvironment of PDAC contributes to its
immune evasion as well. Therefore, a signiﬁcant interest has arisen to
modulate the PDAC stroma in order to increase the efﬁcacy of therapeu-
tics [7,44–46], such as various transgenicmousemodels inwhich genet-
ically, enzymatically or pharmacologically induced remodeling of the
stroma can increase the penetrance of gemcitabine.
One obstacle facingmost treatment strategies is poor delivery of the
drugs to the site of the tumor. Albumin-bound paclitaxel particles (nab-
Paclitaxel) that interact with endogenous albumin transporters on
endothelial cells of the tumor have been shown to traverse these cells
effectively [47]. Liu et al. have targeted neuropilin-1 (NRP-1) on PDAC
tumor vasculature in order to increase the penetration of silica NPs
into the tumor [48]. They tested the co-administration of silica NPs
and the cyclic tumor-penetrating peptide iRGD in patient-derived
PDAC xenografts with low and high NRP-1 expression levels. They
found that the silica NPs accumulated more extensively in the tumor
with elevated levels of NRP-1 expression.
Our delivery platform has several unique qualities. PNAd-expressing
HEVs are found in LNs normally, but PDAC peculiarly forms de novo
HEVs [25]. Similarly, others have also demonstrated the expression of
HEVs by other types of cancer and their potential implications in
lymph node metastasis [49]. Our histological data indicate that these
HEVs are embedded within the dense stroma. Targeting HEVs here pre-
sents an invaluable opportunity to develop a platform that could deliver
several antineoplastic molecules that modulate the stromal milieu or
enhance the local anti-tumor immune response. As noted in our histol-
ogy data, chemotherapeutic agents could also target ﬁbroblasts that
surround the HEV, as demonstrated by their high expression of
caspase-3.
Our deliverymethod can also target metastatic lesions hidden in the
LNs. We have demonstrated previously that MECA79-coated particles
can localize to HEVs in lymph nodes [24,50].Wewere unable to address
Fig. 5.Histological analysis of PDAC following treatmentwithMECA79-Taxol-NPs. (a) Immunoﬂuorescence staining of the tumor at the end of the study demonstrated that treatmentwith
MECA79-Taxol-NPs resulted in higher apoptosis (caspase-3+) of cancer cells, lower cellular proliferation (Ki67+), and decreased vascularization (CD31+) (Scale bar = 200 μm).
(b) Quantiﬁcation of the caspase-3+ cells using ImageJ software (***p b 0.001, ANOVA, n = 3 mice/group). The data are presented as the mean and SEM. (c) Representative
immunoﬂuorescence images of the PDAC tumor for markers of vasculature (CD31 and PNAd in green) and apoptosis (caspase-3 in red) following treatment with MECA79-Taxol-NPs
(Scale bar = 200 μm). (d) Quantiﬁcation of the Ki67+ cells using ImageJ software (***p b 0.001, student's t-test, n = 3 mice/group). The data are presented as the mean and SEM.
(e) Representative immunoﬂuorescence images of the PDAC tumor for markers of vasculature (CD31 and PNAd) and proliferation (Ki67) in the no-treatment group (Scale bar = 200
μm for CD31, 100 μm for PNAd). (f) Immunoﬂuorescence staining for collagen I (red) of the PDAC tumor comparing the groups that received no treatment and MECA79-Taxol-NP
(Scale bar = 100 μm).
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LNs), but the efﬁcacy of our strategy to target metastatic niches in LNs
should be explored in the future, as PDAC commonly metastasizes to
local and distant LNs [51]. Many PDAC patients die with advanced me-
tastasis to the liver and lungs [52]. Metastatic lesions in lungs and liver
may also form de novo HEVs. Future speciﬁc metastatic animal models
are required to examine the presence of HEVs in metastatic lesions, es-
pecially in the liver and lungs.
The treatment of complex medical conditions often requires combi-
natorial strategies that target various pathologic arms of the disease.
Though we used a standard chemotherapy drug to demonstrate a
proof of concept in this study, future studies can focus on delivering
more speciﬁcmodulators. One example is to deliver agents that dampen
the activity of regulatory T cells but potentiate the activity of effector
immune cells [53]. The other important feature is that ourNPs target en-
dothelial cells primarily, rather than relying on passive accumulation.
Interestingly, HEVswere foundwithin thedense stromaof thepancreas.
Our delivery platform could provide opportunities to deliver modula-
tors of the extracellular matrix (ECM) to PDAC as well. Finally, the po-
tential signiﬁcance of our HEV-targeted delivery platform lies in its
capacity to provide molecular imaging to detect the early formation of
malignant tumors and LN metastasis. Expansion of HEVs is one of the
earliest changes that occurs in LNs following invasion by cancer, a phe-
nomenon that can be traced by devising tagged MECA79-NPs [17]. Fur-
thermore, de novo formation of HEV in the pancreas can be detected
with high positive predictive value, given that a normal pancreas does
not contain HEVs. Indeed, the development of a molecular imaging
technique that will enhance the ability to properly diagnose and stage
PDAC in its nascent phase is a major unmet need that could improve
its overall outcome.
Several limitations can be addressed in the future to further advance
our delivery platform. Here, we used Taxol, but one could envision bet-
ter efﬁcacy with somewhat more promising drugs, such as gemcitabine
or devising a combinatorial strategywith a newer agent such as oteracil
[54]. Assessment of the efﬁcacy of our delivery platform in treatingmet-
astatic niches in peripheral organs would also be a valuable pursuit, as
these niches alsomay express HEV. Such an investigationwould require
the development of a predictable mouse model with metastatic PDAC
lesions. Lastly, a more comprehensive examination of the pattern of
HEV formation within the tumor, in regard to its vicinity with actual
tumor or vasculature, its development, and its progression can greatly
help to better predict and/or develop effective therapeutic strategies. Fi-
nally, testing the efﬁcacy of our delivery platform in other types of HEV-
bearing malignancies would add greater rigor.
Of note, emerging data indicate the presence of HEVs in othermalig-
nancies, such as metastatic melanoma, adenocarcinoma of the colon,
breast cancer, and non-small cell lung cancer [55,56]. Therefore, our
new delivery platform can provide an avenue for the development of
the next generation of nano-targeted modalities for the treatment of le-
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